NRSNW
NeuroSense Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.05
+0.00%Sep 3, 2026, 16:00 UTC
NeuroSense Therapeutics announced a redesigned, capital-efficient development strategy for its ALS drug PrimeC, including an AI-enabled formulation characterization, a comparative study against edaravone, and an optimized Phase 3 PARAGON trial design, with a New Drug Submission to Health Canada targeted for December 2026.
Source:Aug 6, 2026, 15:29 UTC
NeuroSense Therapeutics completed the pre-NDS process with Health Canada for its ALS drug PrimeC, receiving final meeting minutes that align on the planned submission content and structure, and is advancing toward a December 2026 filing.
Source:Jun 29, 2026, 13:30 UTC
NeuroSense Therapeutics achieved the primary endpoint in a Phase 2b ALS study with PrimeC, showing statistically significant reduction of TDP-43.
Source:Jun 11, 2026, 13:00 UTC
NeuroSense Therapeutics Ltd. was granted a South Korean patent covering its PrimeC composition for ALS treatment.
Source: